ViTAA Medical Solutions and the Montreal Research Ecosystem

Developing innovative medical solutions is a complex challenge involving many factors and a progressive environment, as is the case in Montreal, where the combination of world-class academic resources, a solid and modern research infrastructure, international collaborations and strong government support has led this Canadian city to become a major hub for clinical research in North America. According to Denis Bilodeau, founding owner of iR&D2 Inc and Vice-President, Clinical Operations at ViTAA Medical Solutions, these are the characteristics that Montreal offers for conducting effective clinical research: 

- It is home to renowned academic institutions, such as the University of Montreal and McGill University, which treat a broad patient base, promote clinical research and attract talented researchers from around the world.

- It has a dynamic research ecosystem of clinical researchers, pharmaceutical companies and government agencies that collaborate closely in a synergy that fosters innovative research projects.

- Its state-of-the-art clinical infrastructure is robust, with well-equipped research centers, teaching hospitals, specialized facilities and cutting-edge technologies where high-quality clinical trials are conducted.

- It fosters international collaboration, attracting researchers and healthcare professionals from all over the world. The city regularly hosts international conferences, congresses and scientific events, fostering knowledge exchange and collaboration between researchers from different regions.

- Strong government support from the Canadian and Quebec governments, which focus on clinical research and invest in funding and incentive programs to stimulate innovation in healthcare on a large scale.

The Centre de recherche de l'Institut universitaire de gériatrie de Montréal (CRIUGM) is a research center specializing in the study of aging, neurodegenerative diseases and cognitive health. 

In recent years, Mila (Institut québécois d'intelligence artificielle - Quebec Institute of Artificial Intelligence, formerly the Montreal Institute of Learning Algorithms) has brought together a community of more than 1,200 researchers specialized in machine learning and dedicated to scientific excellence and innovation.

This community drives knowledge by enabling the study of large datasets and thus paving the way towards new therapies and clinical assessment tools. 

How would you describe the impact of artificial intelligence on the development of medical diagnostic software? 

Mr. Bilodeau: Artificial intelligence (AI) is playing an increasingly important role in the development of medical diagnostic imaging software. Here are some key points about its importance:

1. Automatic image analysis: AI makes it possible to automate and improve the analysis of medical images. Machine learning algorithms can be trained on huge datasets of medical images to recognize and interpret anatomical structures, lesions, pathologies and other features of clinical interest. This can speed up the interpretation process and help clinicians make more informed decisions.
2. Early detection of pathologies: AI can be used to develop software capable of detecting early signs of pathologies. For example, in the field of radiology, AI can help identify early signs of cancers, cardiac abnormalities, strokes, neurological diseases and other conditions. This enables faster diagnosis and can contribute to earlier interventions and better clinical outcomes.
3. Improve diagnostic accuracy: AI can contribute to improving diagnostic accuracy by helping physicians interpret medical images. AI algorithms can detect subtle patterns and features that might escape the human eye, helping to identify crucial diagnostic information. Physicians can then benefit from an automated second opinion, which can reduce diagnostic errors and improve clinical decision-making.
4. Personalization of treatments: AI can also help personalize treatments based on the individual characteristics of each patient. By analyzing medical images and clinical data, AI can, in some cases, predict a patient's response to a specific treatment, identify biomarkers predictive of drug response or resistance, and help physicians develop personalized treatment plans.
5. Ongoing research and development: AI offers new research and development opportunities in the field of medical imaging. Researchers can use AI to analyze large medical imaging datasets, identify new associations and trends, for example between imaging and genomics, and develop new imaging techniques. This leads to innovation and advances in clinical practice.

In cardiovascular medicine, AI-based systems, such as IBM's Watson, could bring new applications in cardiovascular imaging, cardiovascular risk prediction and new drug targets.

In short, artificial intelligence is set to play a key role in the development of medical imaging software, enabling automatic image analysis, early detection of pathologies, more accurate diagnosis, personalized treatment and ongoing research. This opens up new perspectives for improving healthcare and optimizing patient outcomes.

 

What is ViTAA Medical Solutions?

Mr. Bilodeau: The ViTAA Medical Solutions platform is designed to help healthcare professionals better assess vascular conditions primarily by analyzing CT scans. The application aims to use advanced technologies, such as artificial intelligence (AI) and image processing, to extract valuable information about vessel structure, elasticity and blood flow to provide quantitative and qualitative analyses to physicians. 

One of the main applications under development by ViTAA Medical Solutions is the evaluation of abdominal aortic aneurysms, a serious and urgent condition, as 80% of ruptures result in death. Its software uses sophisticated algorithms to eventually detect, measure and potentially track abdominal aortic aneurysms, providing accurate measurements and key information to physicians for informed decision making. Treatment of abdominal aortic aneurysms is crucial to prevent rupture, reduce the risk of mortality, preserve organ function, and improve patients' quality of life. It is essential to diagnose and treat these aneurysms as early as possible to avoid serious and life-threatening complications. The software is currently tested in clinical studies and is designed to be user-friendly and intuitive, allowing healthcare professionals to easily integrate these tools into their daily clinical practice.

How important is the human factor in the development of this software?

Mr. Bilodeau: In our Montreal grouping, we would like to highlight the leadership of Dr. Gilles Soulez of CHUM, whose work in clinical research in interventional radiology is of great importance. 

As part of the ViTAA Registry of abdominal aortic aneurysms, he was a key partner in establishing a North American radiological protocol specific to the project. In addition, he rapidly recruited subjects and bridged the different imaging modalities, namely CT, MRI and ultrasound. More broadly, he works at the interface between fundamental research and clinical practice, collaborating with scientists, engineers and other clinicians to develop innovative solutions for patients. His contributions to the development of new techniques, translational research and the training of young clinicians have had a significant impact on the field of interventional radiology. His collaboration with other researchers and his ongoing commitment to medical innovation have made him an influential figure in the field of clinical radiology research.

VITAA Medical Solutions is also proud of working with Dr. Kent Mackenzie, Chief and Director of the Division of Vascular Surgery at the MUHC and McGill University, in the context of the ViTAA Registry.

 

About Denis Bilodeau, BSc, DIA, MBA :

Denis has 35 years of diversified experience in patient care, clinical research on medical devices, drug development, central laboratories, genomics, medical imaging and cell therapy, in organizations such as Sandoz, Aventis, Génome Québec, the Montreal Heart Institute, Ceapro, NWL, SoundBite Medical, ViTAA Medical and Atonco Pharma SAS, both nationally and internationally. 

Passionate about life sciences and the pressing need for ever better therapies, he founded iR&D2 Inc. 22 years ago and has led numerous research initiatives such as CARTaGENE, one of the largest population genomic registries in Canada, and has successfully led clinical research programs resulting in approvals in the US, Canada and Europe. He is a member of the Ordre des administrateurs agréés du Québec. 

On a daily basis, Denis works closely with academic and private clinical research teams to implement clinical programs leading to safer and more effective treatments and medical technologies in a wide range of indications, including cardiovascular disease, cancer, aortic aneurysms and neurological diseases. Denis holds an MBA and DIA from Concordia University in Montreal and a BSc in Life Sciences from Laval University in Quebec.